SPY312.23+1.71 0.55%
DIA258.42+1.11 0.43%
IXIC10,207.63+53.00 0.52%

Akebia Therapeutics Announces Approval Of Vadadustat In Japan For The Treatment Of Anemia Due To Chronic Kidney Disease In Dialysis-Dependent And Non-Dialysis Dependent Adult Patients

First Regulatory Approval for Akebia's HIF-PHI Marks Beginning of Next Phase of Akebia's Growth Story CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a

Benzinga · -

First Regulatory Approval for Akebia's HIF-PHI Marks Beginning of Next Phase of Akebia's Growth Story

CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD). Mitsubishi Tanabe Pharma Corporation (MTPC), Akebia's collaboration partner in Japan for vadadustat, has obtained manufacturing and marketing approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour and Welfare in Japan on June 29, 2020. Vadadustat will be marketed by MTPC in Japan under the trade name VAFSEO™.